Inventaire - i tuoi amici e le tue comunità sono la tua biblioteca

Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis.

autore

Konstantinos Melissaropoulos

Stamatis-Nick Liossis

pubblicato in: Rheumatology International

data di pubblicazione: 2018-06-04

Cita articoli 45

Data

Titolo

Autori

2017-05-01

Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts

Peter Dorfmuller, Jonathan London
2017-05-15

Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

Edward A. Clark
2016-04-28

Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor
2016-09-06

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Caroline Gordon, Michelle A. Petri, Janet Pope, Kenneth C. Kalunian, Megan E B Clowse
2016-10-13

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease

Konstantinos Melissaropoulos, Theodora Simopoulou, Stamatis-Nick Liossis, Lazaros I Sakkas
2015-02-03

Abnormal B lymphocyte activation and function in systemic sclerosis
2015-09-08

Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity

Takashi Matsushita, Minoru Hasegawa
2015-09-28

Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis.

Dimitrios P. Bogdanos, Theodora Simopoulou, Christina G. Katsiari
2015-09-29

Systemic Sclerosis Patients Present Alterations in the Expression of Molecules Involved in B-Cell Regulation
2014-01-17

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
2014-04-29

The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease
2013-03-01

CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation

Gerd-Rüdiger Burmester
2013-10-03

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Murray Baron, Patricia E Carreira, Ariane I. Herrick, Janet Pope, Otylia Kowal-Bielecka, Gabriele Valentini, Marco Matucci-Cerinic, Ulf Müller-Ladner, Gabriela Riemekasten, Madelon C Vonk, Maureen D. Mayes, Douglas J Veale, Peter A Merkel, Dinesh Khanna, Robert Simms, Barri J Fessler, Frank H J van den Hoogen, Armando Gabrielli, Raymond P Naden, Thomas A Medsger, James R Seibold, Mary Ellen Csuka, Vivien M Hsu, Stanislav Sierakowski, Jaap Fransen, Yannick Allanore, Oliver Distler, Bashar Kahaleh, Ulrich Walker, Lorinda Chung, Laszlo Czirjak, Sergio A Jimenez
2013-11-29

Rituximab in severe, treatment-refractory interstitial lung disease

Toby Maher, Elisabetta Renzoni
2013-10-28

B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis

Seiamak Bahram, Ghada Alsaleh
2013-01-01

B cells tell scleroderma fibroblasts to produce collagen

Stamatis-Nick Liossis
2011-02-02

Treatment with TNFα blockers induces phenotypical and functional aberrations in peripheral B cells.
2011-11-24

B cells and autoimmunity
2010-01-01

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study
2010-03-01

Association of the FAM167A-BLK region with systemic sclerosis

Minoru Hasegawa, Naoyuki Tsuchiya, Aya Kawasaki
2010-03-25

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

Maria De Santis, Barbara Tolusso, Gianfranco Ferraccioli
2010-11-25

Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease

Gaetano Zizzo, Francesco Varone, Stefano Alivernini, Maria De Santis, Alice Mannocci, Gianfranco Ferraccioli, Giuseppe La Torre
2009-02-01

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis

Robert Lafyatis, Michael York, Giuseppina Farina, Robert Simms
2009-05-01

Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance
2009-05-15

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

Stamatis-Nick Liossis
2009-10-08

BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians

Pravitt Gourh, Antonio Fernandez-Nebro, Norberto Ortego-Centeno, Javier Martin, Gabriela Riemekasten, John D Reveille
2009-11-16

Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis

Takashi Matsushita
2008-02-15

Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab

Ai Lyn Tan, Andy C Rawstron
2008-05-08

CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma

Kazuhiro Komura, Minoru Hasegawa
2008-11-01

CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model

Kazuhiro Komura
2007-03-01

Systemic sclerosis: a prototypic multisystem fibrotic disorder
2007-03-01

Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis

Naoyuki Tsuchiya, Minoru Hasegawa

Articolo - wd:Q54977033

Benvenuto su Inventaire

la biblioteca dei tuoi amici e della tua comunità

ulteriori informazioni